WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The company was founded in 2000 and is based in Shanghai.
|Presentation at the 2009 UBS Global Healthcare Services Conference|
|November 2008 Non-deal Roadshow|
|Q2 Earnings Presentation|
|Q4 2007 Earnings Presentation|
|Q3 2007 Earnings Presentation|
WuXi is recognized as a strong growth company that has delivered solid financial performance since its inception, including 98% growth in net revenues and 70% growth in adjusted EBITDA in the third quarter of 2008 compared to the comparable period in 2007. Our management has strategies in place to build on this record and sustain long-term growth. The three key priorities for 2009 are to expand and strengthen WuXi's core laboratory services business to meet increasing customer demand; to establish our good laboratory practice (GLP) toxicology center in Suzhou, which will be a strong value driver for WuXi in 2010 and beyond; and to initiate operations in our commercial-scale API manufacturing site in Jinshan. Success in these three areas is expected to deliver strong customer benefit and drive growth in shareholder value for many years to come. Our goal is to be the outsourcing partner of choice from bench to market.
Last changed at 30-Nov-2009 09:25AM by ChinaSecurities
Presentation at the 2009 UBS Global Healthcare Services Conference
February 10, 2009